AI in Clinical Development Summit to Showcase Life Sciences and Technology Leaders Driving Real-World AI Impact

Innovators share how organizations are moving from AI ambition to delivering scaled and measurable impact on clinical trials

NEW YORK--(BUSINESS WIRE)--QuantHealth, the global leader in AI-powered clinical trial simulation and a trusted partner to 12 of the top pharmaceutical companies, today announced that the AI in Clinical Development Summit will once again convene leading voices across the life sciences, technology, and regulatory sectors to explore how AI is accelerating clinical development and being successfully implemented at scale. The event will take place on May 27, 2026, in New York City.

As the premier forum for clinical development innovation, the AI in Clinical Development Summit will feature insights from C-suite and senior leaders at AstraZeneca, Bristol Myers Squibb, Sanofi, and Roche, alongside technology and innovation leaders from Accenture, AWS, Databricks, and ZS.

Featured speakers include:

• Jorge Reis-Filho: Chief of AI for Science Innovation, AstraZeneca
• Emmanuel Frenehard: Chief Digital Officer, Sanofi
• Lionel Bascles: SVP & Global Head of eDevelopment, Sanofi
• Simon Davies: SVP & Head of Data & Quantitative Sciences, Bristol Myers Squibb
• Matteo DiTommaso: SVP of R&D Business Insights & Technology, Bristol Myers Squibb
• Ken Levine: Head of Business Assessment, Pfizer
• Okan Ekinci, MD, MBA: Head of Digital Technology & CMIO, Roche Information Solutions

Additional speakers, including thought leaders Sean Khozin, MD, MPH, CEO of the CEO Roundtable On Cancer and Project Data Sphere, and Craig Lipset, Co-Chair of the Digital Trials & Research Alliance, will join throughout the day for fireside chats, expert panels, real-world case studies, and interactive workshops.

At the Summit, attendees will gain practical strategies and actionable insights to:

• Accelerate trial timelines and improve decision-making
• Move from AI pilots to enterprise-wide adoption with measurable outcomes
• Build intelligent clinical development organizations for sustained competitive advantage
• Move from regulatory uncertainty to go-to-market confidence
• Drive organization-wide adoption and operationalize AI across teams

“The conversation around AI in clinical development has shifted from possibility to proof,” said Orr Inbar, CEO of QuantHealth. “What matters now is not whether AI can transform clinical trials, but how organizations can successfully implement it at scale and measure real impact. This summit brings together leaders who are doing exactly that – turning AI into measurable results.”

Now in its third year, this invite-only summit has become a cornerstone gathering for life sciences and technology leaders leveraging AI to accelerate clinical trials, gain a competitive advantage, and bring more effective therapies to patients faster. The highly anticipated event has previously been attended by VP-level leaders and above from 18 of the top 20 pharmaceutical companies, along with leading and emerging biotechnology organizations.

To learn more and request an invitation, visit: https://www.qhsummit.com/

About QuantHealth

QuantHealth is the global leader for AI clinical trial simulation, bringing together the industry’s most advanced clinical trial simulations portfolio — 600+ trial simulations across 30 diseases with up to 90% prediction accuracy — and the category's largest real-world data set to help life sciences and biotechnology organizations improve the potential of clinical trial successes. QuantHealth solutions use real-world data and predictive modeling to simulate trials at scale, optimize protocols, reduce risk, and accelerate timelines. The company is a trusted partner for twelve of the top 20 global pharmaceutical companies.